Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Salix: FDA Approves Fulyzaq 125 Mg Tablets For Diarrhea In HIV/AIDS Patients

Salix Pharmaceuticals, Ltd. (SLXP: Quote) Wednesday said the Food and Drug Administration approved Fulyzaq, or crofelemer, 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS, who are on anti-retroviral therapy or ART.

Fulyzaq is a locally-acting, minimally-absorbed drug derived from a botanical source. It is not available synthetically and Salix has the right to the manufacturing process for producing Fulyzaq from the biologic source.

Patents for Fulyzaq is expected to provide intellectual property protection to 2018. Fulyzaq is eligible for market exclusivity for five years as a new molecular entity in the U.S. and the product may be entitled to patent term restoration. The drug is expected to become accessible to patients in early 2013.

The drug is believed to act by blocking chloride secretion and thus reducing the accompanying high volume water loss as seen in HIV-associated diarrhea.

It is this secretion that is said to lead to diarrhea with the associated symptoms of dehydration, electrolyte imbalance, abdominal cramping, urgency and increased frequency.

The FDA approval of Fulyzaq is based on a randomized, double-blind, placebo-controlled and placebo-free, multi-center study of 374 HIV-positive patients on ART, with a history of diarrhea for one month or more.

The primary efficacy endpoint was the proportion of patients experiencing less than or equal to two watery bowel movements per week, during at least two of the four weeks of the placebo-controlled phase.

Data showed that a significantly larger proportion of patients taking Fulyzaq 125 mg twice daily experienced clinical response compared to patients in the placebo group. Significant reductions from baseline to the end of the double-blind period also were observed for the number of watery bowel movements per day, and daily stool consistency score.

The Phase 3 study showed that Fulyzaq did not influence the efficacy or safety of the patients' HIV medications. The most common adverse reactions were respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.

SLXP closed at $40.47 on Monday.

Register
To receive FREE breaking news email alerts for Salix Pharmaceuticals Ltd and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The U.K. economy grew more than estimated in the second quarter and the current account deficit widened from the first quarter, the Office for National Statistics said Tuesday. Gross domestic product grew 0.9 percent sequentially, up from the prior estimate of 0.8 percent. The annual growth was confirmed at 3.2 percent. Eurozone inflation slowed in September, as expected, to the lowest since late 2009 and the unemployment rate remained stable at a double digit level in August putting pressure on the European Central Bank to launch a full-blown easing. Inflation came in at 0.3 percent, slower than August's 0.4 percent. This was the lowest since October 2009, when prices fell 0.1 percent. Chinese authorities on Tuesday eased some rules for mortgages for buying a second home, in a bid to boost the housing market. The People's Bank of China and the China Banking Regulatory Commission said in a joint statement that buyers who already own one apartment, but have paid off the mortgage...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.